Literature DB >> 26652832

Pharmacokinetics and pharmacodynamics in antibiotic dose optimization.

Sherwin K B Sy1,2, Luning Zhuang1,3, Hartmut Derendorf1.   

Abstract

INTRODUCTION: Identifying the optimized dosing regimen and algorithm is critical in the development of antibiotics. Suboptimal regimens and inappropriate choice of drug give rise to drug-resistant bacteria which have limited the therapeutic utility of many commercially available antimicrobial agents. Strategies to optimize therapy of antimicrobial candidates to speed up the development process are urgently needed. AREAS COVERED: We examined pharmacokinetics and pharmacodynamics of antimicrobial agents with modeling and simulation approaches. The approach that is based on minimum inhibitory concentration to evaluate antimicrobial dosing strategy is widely utilized in drug development. The modeling approach utilizing information from time-kill kinetic studies is a tool that can provide more information on the time-course of bacterial response to a particular dosing regimen. Animal studies of dosing regimens that mimic human pharmacokinetics are another option to evaluate antimicrobial efficacy. Empirical, semi-mechanistic and mechanistic models of bacterial dynamics and development of drug resistance in response to drug therapy are discussed. EXPERT OPINION: Both theories and applications of these approaches provide an overall understanding of how the tools can streamline drug development process and help make crucial decisions. Many opportunities and potentials are presented to incorporate more rigorous integration of PK-PD modeling approaches even at preclinical stage to extrapolate to clinical settings, thus enabling successful trials and optimizing dosing strategies in relevant populations where the drug is mostly used.

Entities:  

Keywords:  PK-PD modeling; antibiotics; in vitro models; translational research

Mesh:

Substances:

Year:  2015        PMID: 26652832     DOI: 10.1517/17425255.2016.1123250

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  20 in total

Review 1.  Antibiotic resistome of Salmonella typhi: molecular determinants for the emergence of drug resistance.

Authors:  Awanish Kumar; Anil Kumar
Journal:  Front Med       Date:  2021-06-04       Impact factor: 4.592

Review 2.  Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime-Avibactam Combination: A Model-Informed Strategy for its Clinical Development.

Authors:  Sherwin K B Sy; Luning Zhuang; Serubbabel Sy; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2019-05       Impact factor: 6.447

3.  Semimechanistic Modeling of Eravacycline Pharmacodynamics Using In Vitro Time-Kill Data with MIC Incorporated in an Adaptive Resistance Function.

Authors:  Ken Nguyen; Timothy J Bensman; Xiaohui Tracey Wei; Jason N Moore
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

4.  Pharmacodynamic Evaluation of Fosfomycin against Escherichia coli and Klebsiella spp. from Urinary Tract Infections and the Influence of pH on Fosfomycin Activities.

Authors:  Nayara Helisandra Fedrigo; Josmar Mazucheli; James Albiero; Danielle Rosani Shinohara; Fernanda Gomes Lodi; Ana Cristina Dos Santos Machado; Sherwin K B Sy; Maria Cristina Bronharo Tognim
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

5.  Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase.

Authors:  James Albiero; Josmar Mazucheli; Juliana Pimenta Dos Reis Barros; Marcia Maria Dos Anjos Szczerepa; Sheila Alexandra Belini Nishiyama; Floristher Elaine Carrara-Marroni; Serubbabel Sy; Matthew Fidler; Sherwin K B Sy; Maria Cristina Bronharo Tognim
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

6.  Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae.

Authors:  James Albiero; Sherwin K B Sy; Josmar Mazucheli; Silvana Martins Caparroz-Assef; Bruno Buranello Costa; Janio Leal Borges Alves; Ana Cristina Gales; Maria Cristina Bronharo Tognim
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

7.  Tracking Cefoperazone/Sulbactam Resistance Development In vivo in A. baumannii Isolated from a Patient with Hospital-Acquired Pneumonia by Whole-Genome Sequencing.

Authors:  Xiaofen Liu; Huajun Zheng; Weipeng Zhang; Zhen Shen; Miao Zhao; Yuancheng Chen; Li Sun; Jun Shi; Jing Zhang
Journal:  Front Microbiol       Date:  2016-08-19       Impact factor: 5.640

Review 8.  The Role of PK/PD Analysis in the Development and Evaluation of Antimicrobials.

Authors:  Alicia Rodríguez-Gascón; María Ángeles Solinís; Arantxa Isla
Journal:  Pharmaceutics       Date:  2021-06-03       Impact factor: 6.321

9.  Determining optimal dosing regimen of oral administration of dicloxacillin using Monte Carlo simulation.

Authors:  Wei Yu; Jinru Ji; Tingting Xiao; Chaoqun Ying; Jiaheng Fang; Ping Shen; Yonghong Xiao
Journal:  Drug Des Devel Ther       Date:  2017-06-28       Impact factor: 4.162

10.  Evaluation of Ceftazidime/Avibactam Administration in Enterobacteriaceae and Pseudomonas aeruginosa Bloodstream Infections by Monte Carlo Simulation.

Authors:  Yuanyuan Dai; Wenjiao Chang; Xin Zhou; Wei Yu; Chen Huang; Yunbo Chen; Xiaoling Ma; Huaiwei Lu; Rujin Ji; Chaoqun Ying; Peipei Wang; Zhiying Liu; Qingfeng Yuan; Yonghong Xiao
Journal:  Drug Des Devel Ther       Date:  2021-07-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.